Alphatec (ATEC) to Post Quarterly Earnings on Tuesday

Alphatec (NASDAQ:ATEC) is anticipated to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of $0.09 per share and revenue of $211.2680 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Alphatec Stock Up 5.0%

NASDAQ ATEC opened at $8.67 on Tuesday. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.12 and a current ratio of 1.90. The firm has a 50-day simple moving average of $8.51 and a 200 day simple moving average of $11.24. Alphatec has a twelve month low of $6.82 and a twelve month high of $23.29. The stock has a market cap of $1.33 billion, a PE ratio of -10.57 and a beta of 0.85.

Wall Street Analysts Forecast Growth

ATEC has been the topic of several recent research reports. Canaccord Genuity Group decreased their price objective on Alphatec from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Lake Street Capital reiterated a “buy” rating and set a $15.00 target price on shares of Alphatec in a research report on Wednesday, May 6th. Wells Fargo & Company lowered their target price on shares of Alphatec from $28.00 to $14.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. JPMorgan Chase & Co. cut their price target on shares of Alphatec from $24.00 to $16.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, BMO Capital Markets began coverage on Alphatec in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $11.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alphatec has an average rating of “Moderate Buy” and an average target price of $17.29.

Insider Activity

In other news, Director Karen K. Mcginnis sold 6,050 shares of Alphatec stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $8.01, for a total value of $48,460.50. Following the completion of the transaction, the director owned 94,671 shares in the company, valued at approximately $758,314.71. The trade was a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 13.48% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATEC. Morgan Stanley raised its position in shares of Alphatec by 22.0% during the fourth quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company’s stock worth $91,333,000 after acquiring an additional 784,191 shares during the last quarter. State Street Corp lifted its stake in shares of Alphatec by 6.4% during the fourth quarter. State Street Corp now owns 2,889,240 shares of the medical technology company’s stock valued at $60,790,000 after acquiring an additional 174,287 shares during the period. Geode Capital Management LLC boosted its holdings in Alphatec by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,828,026 shares of the medical technology company’s stock valued at $59,511,000 after acquiring an additional 32,465 shares during the last quarter. Millennium Management LLC boosted its holdings in Alphatec by 292.2% in the fourth quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company’s stock valued at $46,834,000 after acquiring an additional 1,658,349 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in Alphatec by 59.0% in the third quarter. Two Sigma Investments LP now owns 1,794,324 shares of the medical technology company’s stock worth $26,089,000 after purchasing an additional 665,634 shares during the period. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.